has provided consultation to Eisai, Biogen, Lilly, Roche, Genentech, Bolden, Novo Nordisk, Prothena, Acumen Pharmaceuticals, Labcorp, Alector, Corium, Kisbee, Neurophet, Icometrix and AbbVie
We were thus prompted to explore the intriguing hypothesis that GSH-dependent control of ROS could play a role in defining the distinctive metabolic signaling of MZB and FoB
This dual action supports both weight management and overall metabolic health
Single nucleotide polymorphisms (SNPs) associated with, and predictive of, growth response after 1 and 2 years on growth hormone (GH) therapy in girls with Turner syndrome (TS)
Regular follow-up appointments are essential to monitor treatment response, side effects, weight changes, and psychological wellbeing